A Florida district court did not abuse its discretion in refusing Lakeland Regional Medical Center Inc.’s request to certify a class seeking damages against Astellas US LLC and Astellas Pharma US Inc. for the alleged unlawful tying of their drug Adenoscan to a cardiac test, the U.S. Court of Appeals for the Eleventh Circuit has ruled.
An Eleventh Circuit panel affirmed the decision by U.S. District Court for the Middle District of Florida that Lakeland was not a viable class representative because it didn’t buy the drug directly from Astellas and, as a result, the federal antitrust law’s direct purchaser rule bars Lakeland’s own treble damages claim.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
